Christopher Rofe

Incidental findings during lung low‐dose computed tomography cancer screening in Australia and Canada, 2016–21: a prospective observational study

Asha Bonney, Diane M. Pascoe, Mark W. McCusker, Daniel Steinfort et autres

OBJECTIVES: To investigate the type and frequency of incidental findings in people at high risk of lung cancer who undergo baseline low-dose computed tomography (LDCT) lung cancer screening in Australia and Canada. STUDY DESIGN: Prospective observational study; sub-study of the single-arm International …

au, us, ca (code pays fourni par la source)

14 The impact of non-invasive fractional flow reserve (ctFFR) on clinical decision-making and cost savings in the investigation of coronary artery disease: a 15-month audit at borders general hospital

James W. Henderson, Apurva Sinha, Anda Bularga, Joy Dawson et autres

gb (code pays fourni par la source)

Coronary artery calcification detected on low‐dose computed tomography in high‐risk participants of an Australian lung cancer screening program: A prospective observational study

Asha Bonney, Michelle Hui Juan Chua, Mark W. McCusker, Diane M. Pascoe et autres

BACKGROUND AND OBJECTIVES: Coronary artery calcification (CAC) is a frequent additional finding on lung cancer screening (LCS) low-dose computed tomography (LDCT). Cardiovascular disease (CVD) is a major cause of death in LCS participants. We aimed to describe prevalence of incidental CAC detected …

au, ca (code pays fourni par la source)

Impact of COVID-19 Pandemic on Cardiovascular Testing in Asia

Takashi Kudo, Ryan Lahey, Cole B. Hirschfeld, Michelle Claire Williams et autres

Background: The coronavirus disease-2019 (COVID-19) pandemic significantly affected management of cardiovascular disease around the world. The effect of the pandemic on volume of cardiovascular diagnostic procedures is not known. Objectives: This study sought to evaluate the effects of the early phase of …

jp, us, gb, sa, in, kr, kz, ir, sg, il, au, ca, ph, at (code pays fourni par la source)

177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial

Sarennya Pathmanandavel, Megan Crumbaker, Andrew On Wah Yam, Andrew V Nguyen et autres

Background:177Lutetium PSMA-617 (Lu-PSMA-617) is an effective therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently and combination therapies may improve outcomes. We report the final safety and efficacy results of a phase I/II study combining Lu-PSMA-617 with idronoxil (NOX66), …

au, nz (code pays fourni par la source)

Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World

Cole B. Hirschfeld, Leslee J. Shaw, Michelle Anne Williams, Ryan Lahey et autres

OBJECTIVES: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-U.S. institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. BACKGROUND: The COVID-19 pandemic has disrupted the care of many …

us, gb, br, au, ca, cn, mn, ru, jp, dk, hu, il, ph, at (code pays fourni par la source)

Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial).

Sarennya Pathmanandavel, Megan Crumbaker, Andrew On Wah Yam, Christopher Rofe et autres

103 Background: 177LuPSMA – 617 is a promising therapy for metastatic castrate-resistant prostate cancer (mCRPC). However, treatment resistance occurs frequently and synergistic combination therapy may improve outcomes. We combined 177LuPSMA – 617 with idronoxil (NOX66), an inhibitor of external NADH oxidase type …

au (code pays fourni par la source)

Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Megan Crumbaker, Sarennya Pathmanandavel, Andrew On Wah Yam, Andrew V Nguyen et autres

au, ca (code pays fourni par la source)

Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).

Louise Emmett, Sarennya Pathmanandavel, Megan Crumbaker, Christopher Rofe et autres

5557 Background: There is no established standard of care post cabazitaxel in men with mCRPC. Ongoing trials in 177LuPSMA-617 have demonstrated good efficacy and safety, but synergistic combinations may further improve treatment responses. Idronoxil (NOX66) inhibits external NADH oxidase type 2 with …

au (code pays fourni par la source)

089 Breaking the cycle of chronic daily headache with a low-dose subcutaneous lignocaine and ketamine infusion

Christopher Rofe, Raymond Garrick, David Burke, Bruce James Brew et autres

Introduction Management of chronic migraine includes correcting analgesic rebound headache and implementing suitable medication for prevention and acute episodes. However, in many cases this management paradigm oversimplifies the complexity of chronic migraine, particularly the entrenched central pathways that perpetuate chronic migraine. Intravenous …

au (code pays fourni par la source)

Evaluation of the impact of a low dose subcutaneous lignocaine and ketamine infusion utilising nerve excitability studies in a chronic migraine population.

Christopher Rofe

Migraine is a common condition in which the diagnosis is based on clinical grounds. There is no clinically available biophysical marker that can evaluate migraine. Migraines are linked to functional brain changes in the absence of structural abnormalities. A clinically useful tool …

Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis

Samantha Warhurst, Christopher Rofe, Bruce James Brew, Deborah J. Bateson et autres

Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk …

nz, au, ch (code pays fourni par la source)